GRASLND is a prognostic biomarker and associated with immune infiltration in bladder cancer

GRASLND has been shown to be a potent biomarker in a variety of cancers. However, studies on GRASLND and bladder cancer have been limited. Therefore, this study aimed to analyze the expression of GRA SLND and their relationship with clinicopathological features, prognosis and immune cell infiltration in patients of bladder cancer. The RNA sequencing data and clinical information of 412 patients with bladder cancer and 19 normal subjects were obtained from The Cancer Genome Atlas database. Our results demonstrated that GRASLND was highly expressed in bladder cancer (P < 0.001) and could effectively distinguish bladder cancer tissue from normal bladder tissue (area under the curve = 0.805). Moreover, the expression of GRASLND was significantly correlated with pathologic stage, pathologic T stage, pathologic N stage, histologic grade and subtype. Kaplan–Meier curves analysis revealed that patients with high gene expression had shorter overall survival and worse prognosis (hazard ratio = 1.46, P = 0.012). Cox regression analysis indicated that GRASLND expression, Age, Pathologic T stage, Pathologic N stage, Pathologic M stage, Pathologic stage and Subtype were risk factors for overall survival. Immunoinfiltration analysis found that the expression of GRASLND was positively correlated with the enrichment abundance of immune cells such as macrophages, Tgd and Tem. Collectively, our results suggested that GRASLND may be an important biomarker for the diagnosis and predicting prognosis of bladder cancer, and may even be a new therapeutic target.